- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT01381406
Impact of Initiating Tiotropium Alone Versus Initiating Tiotropium in Combination With Fluticasone Propionate/Salmeterol Xinafoate Combination (FSC) on Chronic Obstructive Pulmonary Disease-related Outcomes in Patients With Pre-existing Exacerbations
This was a retrospective cohort design using administrative claims data from Jan 1, 2003 through Sep 30, 2007, representing the years of available data, were used for this study. Managed care enrollees having at least one pharmacy claim for tiotropium (TIO) during the study period were identified as the target population. An index TIO prescription was defined as the first chronologically occurring pharmacy claim for TIO during the period Jan 1, 2004 to Aug 31, 2006, called the enrollment period. The date of the index TIO prescription was termed as the index Rx date, and the 1-year period before the index Rx date was termed as the pre-index period. The period after the index date was termed as the post-index date, and is further divided into a 30-day combination assessment period and a 1-year follow-up period. COPD clinical and economic outcomes were measured in a variable length follow up period.
The combination assessment period, defined as the 30-day period following the index Rx date, was used to categorize patients into 2 cohorts: TIO alone or TIO + FSC (fluticasone propionate/salmeterol xinofoate combination) depending on whether they use FSC in combination with TIO during this period. Combination therapy with TIO + FSC was defined as having an FSC claim on the same date as the TIO claim or a TIO and FSC pharmacy claim with overlapping days supply occurring within 30 days of index Rx date. Enrollees adding FSC for the first time after the 30-day combination assessment period were excluded from the sample, thus ensuring that the TIO-alone cohort is not using FSC. No outcomes were assessed in the 30-day combination assessment period. The 1-year period after the end of the 30-day combination assessment period was termed as the follow-up period and was used to assess all study outcomes. Enrollees were required to be continuously eligible in their health plans during the pre-index and post-index periods for a total of 25 months. An intent-to-treat approach was used for the analyses. Thus, patients identified to be in a drug therapy cohort were considered to be using that therapy during the entire follow-up period, regardless of therapy discontinuations.
Specifically the study hypothesis for the primary outcome being tested was:
Ho: There is no difference in risk of any COPD-related exacerbation between TIO+FSC and TIO cohorts Ha: There is a difference in risk of any COPD-related exacerbation between TIO+FSC and TIO cohorts
Hypothesis for the key secondary outcome of COPD-related costs that was tested was:
Ho: There is no difference in COPD-related costs between TIO+FSC and TIO cohorts Ha: There is a difference in COPD-related costs between TIO+FSC and TIO cohorts
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Real)
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
Descrição
Inclusion Criteria:
- Continuous health plan eligibility in the pre- and post-index periods
- age ≥40 years at the index date
- Presence of at least 1 claim with an ICD-9-CM code for COPD in any diagnosis field (490.xx, 491.xx, 492.xx, 496.xx) in the pre- and post-index period
- ≥1 exacerbation in the pre-index period (defined as a COPD-related Emergency Room visit or hospitalization)
- ≥1 prescription claim for ipratropium or ipratropium/albuterol combination in the pre-index period
- an index event of at least one pharmacy claim for TIO (tiotropium) combination in the pre-index period during the study period (January 1, 2003 through April 30, 2008)
- ≥2 prescriptions for TIO (including the index prescription) during the post-index period
Exclusion Criteria:
- presence of comorbid conditions (respiratory cancer, cystic fibrosis, fibrosis due to tuberculosis [TB], and bronchiectasis, pneumonociosis, pulmonary fibrosis, pulmonary TB, sarcoidosis) during the pre- and post-index periods
- use of FSC in pre-index period
- exacerbation (emergency room visit or hospitalization) within 30 days after the index date
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Modelos de observação: Coorte
- Perspectivas de Tempo: Retrospectivo
Coortes e Intervenções
Grupo / Coorte |
Intervenção / Tratamento |
---|---|
COPD patients
Patients who are at least 40 years of age and diagnosed with COPD using ICD-9 codes of 491.xx, 492.xx, and 496.xx in an administrative claims database.
|
Patients receiving tiotropium bromide at index within the study period.
Outros nomes:
Patients receiving tiotropium bromide plus fluticasone propionate-salmeterol xinafoate combination at time of index within the study period.
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Incidence Rate Per 100 Person Years of Hospitalization or Emergency Department (ED) Visit Related to Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)
Prazo: Data were collected over a maximum period of 4 years
|
A severe exacerbation is defined as one with a primary diagnosis of COPD.
A moderate exacerbation is an ED visit with a primary diagnosis of COPD, a physician visit with a diagnosis of COPD and a prescription for an oral corticosteroid, a physician visit with a diagnosis code for COPD and an antibiotic for respiratory infection, or physician administration of nebulized albuterol within 3 days of an office visit.
Incidence rate is calculated by dividing the number of exacerbations by the number of person years.
Person years adjust for different lengths of follow up for participants.
|
Data were collected over a maximum period of 4 years
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Adjusted Mean Monthly Costs Per COPD Patient by Treatment Group
Prazo: Data were collected over a maximum period of 4 years
|
The mean costs of health care encounters adjusted to control for baseline differences between treatment groups and reported in 2008 United States dollars as calculated with the consumer price index (CPI) are presented.
CPI is standard multiplier for adjusting the cost of goods and services to a single year.
Total costs include pharmacy and medical costs.
Medical costs were computed from the paid amounts of medical claims with a primary diagnosis code for COPD.
COPD-related pharmacy costs were computed from paid amounts of COPD-related prescription medications.
|
Data were collected over a maximum period of 4 years
|
Incidence Rate of Hospitalizations and Emergency Room Visits Per 100 Person Years
Prazo: Data were collected over a maximum period of 4 years
|
Unadjusted incidence rates per 100 person years of chronic obstructive pulmonary disease (COPD)-related hospitalizations and emergency department visits by treatment group are presented.
Incidence rate is calculated by dividing the number of healthcare service encounters by the number of person years of follow up.
Person years adjust for different lengths of follow up for individual participants
|
Data were collected over a maximum period of 4 years
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Doenças Respiratórias
- Doenças pulmonares
- Doenças Pulmonares Obstrutivas
- Doença Pulmonar Obstrutiva Crônica
- Efeitos Fisiológicos das Drogas
- Agentes Neurotransmissores
- Mecanismos Moleculares de Ação Farmacológica
- Parassimpaticolíticos
- Agentes Autônomos
- Agentes do Sistema Nervoso Periférico
- Antagonistas colinérgicos
- Agentes colinérgicos
- Agentes broncodilatadores
- Agentes Antiasmáticos
- Agentes do Sistema Respiratório
- Brometo De Tiotrópio
Outros números de identificação do estudo
- 111266
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em TIO
-
Maia BiotechnologyRecrutamentoCarcinoma pulmonar de células não pequenasPolônia, Austrália, Bulgária, Hungria
-
The Cleveland ClinicAttune FoodsConcluídoHiperlipidemiaEstados Unidos
-
Tomsk National Research Medical Center of the Russian...Uppsala UniversityConcluídoNeoplasias | CérebroFederação Russa
-
Tomsk National Research Medical Center of the Russian...Uppsala UniversityConcluídoLinfoma de Hodgkin Adulto | Linfoma Não-Hodgkin AdultoFederação Russa
-
Boehringer IngelheimRetirado
-
Catholic University of the Sacred HeartConcluídoQualidade de vida | Síndrome de Alergia Sistêmica ao NíquelItália
-
Samus Therapeutics, Inc.RescindidoMielofibrose Primária | Mielofibrose | Pós-policitemia Vera Mielofibrose | Mielofibrose pós-trombocitemia essencialEstados Unidos
-
National Cancer Institute (NCI)RescindidoLinfoma | Tumores SólidosEstados Unidos
-
Memorial Sloan Kettering Cancer CenterConcluídoLinfoma | Tumor Sólido Metastático | Neoplasias Mieloproliferativas (NMP)Estados Unidos
-
Samus Therapeutics, Inc.RescindidoMielofibrose Primária (PMF) | Pós-policitemia Vera mielofibrose (pós-PV MF) | Mielofibrose pós-trombocitemia essencial (MF pós-ET)Estados Unidos